A checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Wendy Balter
Advertisement
Articles by Wendy Balter
Advertisement
Latest Updated Articles
Making the Most of Maturing Oncology BrandsPublished: May 30th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement
2
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
3
Novo Nordisk Stock Reacts to Recent Board Changes
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
